阿戈梅拉丁是一种多向药物,不改变大鼠的基底运动活动
Susana Barbosa-Méndez1, Alberto Salazar-Juarez1
1Molecular Neurobiology and Neurochemistry of Addiction, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico.
Journal of psychiatric research
|June 3, 2025
概括
抗抑郁药阿戈梅拉丁在老鼠中表现出轻度,短暂的镇静作用,剂量高达40毫克/公斤. 较高剂量 (≥10 mg/kg) 不会导致持续的镇静,这表明它可能是一个适合的选择,需要睡眠支持的患者,而没有白天损害.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 行为科学 行为科学
背景情况:
- 传统的抗抑郁药通常会导致白天镇静,限制患者的活动.
- 开发可以改善睡眠的抗抑郁药,而不会在白天产生不良影响至关重要.
- 阿戈梅拉丁通过非镇静催眠机制改善睡眠,但其镇静作用需要研究.
研究的目的:
- 为了评估阿戈梅拉丁的镇静催眠活性.
- 评估不同剂量 (5,10,40毫克/公斤) 和剂量时间对大鼠镇静的影响.
主要方法:
- 在Wistar大鼠中进行行为评估,包括旋转杆,自发运动活动和固定杆测试.
- 以不同剂量和不同时间 (ZT4,ZT10,ZT16,ZT22) 给药.
主要成果:
- 与特拉佐相比,阿戈梅拉丁 (≤40 mg/kg) 产生了轻微的,短暂的镇静作用.
- 剂量为10mg/kg或更高的剂量并没有导致持续的镇静.
- 镇静作用是剂量依赖的和短暂的.
结论:
- 阿戈梅拉丁在经过测试的剂量中不会诱导持续的镇静作用.
- 在较高的阿戈梅拉丁剂量时,可能会发生暂时的运动抑制.
- 研究结果表明,阿戈梅拉丁有潜力在治疗抑郁症时,在白天的损伤最小.
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Drugs Affecting Neurotransmitter Release or Uptake
1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
990
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
990
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
2.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
2.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K


